Representative H&E-stained images of QGP-1 xenografts with and without PTEN loss are shown in Fig. 7B. We administered vehicle control (PBS), the VEGFR3 inhibitor MAZ51, or the MEK inhibitor trametinib to mice bearing QGP-1 xenografts with PTEN loss for 2 weeks (5 days of drug treatment and 2 days of rest) and evaluated tumor growth and invasiveness by H&E staining. This evidence concerns the gene MAP2K7 and neoplasm.